PROTOKOLwiki
COMPOUNDS / PSYCHIATRIC / ADAPTOL
PSYCHIATRIC

ADAPTOL

LOW RISK
BEST FOR:Anxiety●●●●●●●○○○7/10
ADAPTOL · MEBICAR · MEBICARUM · TEMGICOLURIL · MEBIX
AnxiolyticNootropicSoviet / RussianAntioxidantNon-benzodiazepine

Non-benzodiazepine anxiolytic with nootropic properties, used in Russia and Latvia for anxiety, ADHD, and stress-related disorders.

ROUTE / DOSAGE
LOW500mg
STANDARD500-1000mg
HIGH1500mg+
Note: Typically dosed 500mg 2x daily; up to 1500mg/day in divided doses
CYCLE
2-6 weeks extendable to 3 months
BIOAVAILABILITY
~50-70% oral
ACTIVE DURATION
4-6h (subjective)
STORAGE
Room temperature dry away from light
DURATION BREAKDOWN
Total4-8 hours
Onset30min-1h
Come up30-60 min
Peak2-4 hours
Offset2-3 hours
After effects1-2 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
8 documented
Reduced anxiety and tension
Improved stress tolerance
Mild nootropic cognitive support
Decreased hyperactivity and impulsivity
Improved sleep quality
Somatic symptom relief (palpitations, GI discomfort)
Antioxidant activity
No impairment of attention or reaction time
§ 02 — RISKS
Transitory dyspepsia reported in 5.7% of patients
Limited safety data from large-scale controlled trials
Potential for unexpected interactions due to multi-neurotransmitter modulation
Efficacy and safety not established outside Russian/Latvian clinical populations
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Clinical studies in Russia and Latvia demonstrate anxiolytic efficacy for generalized anxiety, panic disorder, and somatic anxiety symptoms with good tolerability. A 2025 noninterventional study of 100 adults found significant reductions in GAD-7 scores and somatic complaints with no unexpected adverse events. Studies in ADHD showed reduced hyperactivity and impulsivity without affecting attention, unlike benzodiazepines. Trials in chronic cerebral ischemia and discirculatory encephalopathy showed improved anxiety, quality of life, and cognitive evoked potentials. Evidence is limited almost entirely to Russian-language publications and observational or open-label designs; large-scale randomized controlled trials in Western populations are lacking.

§ 06 — SOURCES
[1]
Adaptol--verges of possible (PMID 23534281)
pubmed.ncbi.nlm.nih.gov ↗
[2]
Adaptol in the treatment of ADHD (PMID 19738569)
pubmed.ncbi.nlm.nih.gov ↗
[3]
Efficacy of Adaptol 500 mg Tablets in Patients with Anxiety and Somatic Symptoms of Anxiety Disorder (PMID 41303009)
pubmed.ncbi.nlm.nih.gov ↗
[4]
Effectiveness of mobile app combined with Adaptol therapy for anxiety disorder (PMID 39113449)
pubmed.ncbi.nlm.nih.gov ↗
[5]
Adaptol in the treatment of chronic cervicogenic headache (PMID 21905338)
pubmed.ncbi.nlm.nih.gov ↗
[6]
Clinical efficiency of combined therapy using adaptol for atopic dermatitis (PMID 25026806)
pubmed.ncbi.nlm.nih.gov ↗
[7]
Efficacy and safety of adaptol in anxiety-asthenic disorders in chronic cerebral ischemia (PMID 27070467)
pubmed.ncbi.nlm.nih.gov ↗
[8]
Clinical-neurophysiological study of efficacy of adaptol in discirculatory encephalopathy (PMID 22027612)
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT